Duloxetine in the Prevention of Depressive Recurrences: A Randomized, Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
Objective To assess the efficacy of duloxetine 60-120 mg once daily in the prevention of depressive recurrence in outpatients with recurrent major depressive disorder (MDD). Method Eligible patients with at least 3 episodes of MDD (DSM-IV diagnosis) in the past 5 years received open-label duloxetine 60-120 mg/day for up to 34 weeks. Patients meeting response criteria were then randomly assigned to either duloxetine or placebo for up to 52 weeks of double-blind maintenance treatment. The primary outcome measure was time to recurrence of a major depressive episode. Safety and tolerability were assessed via analysis of treatment-emergent adverse events (TEAEs), vital signs, weight, and laboratory measures. Patients were recruited from 43 study centers in 5 European countries (France, Germany, Italy, Russia, and Sweden) and the United States. The study was conducted from March 2005 to January 2008. Results A total of 288 patients were randomly assigned to duloxetine or placebo. Time to a depressive recurrence was significantly longer in duloxetine-treated patients compared with placebo-treated patients (p Conclusions Treatment with duloxetine was associated with a longer time to depressive recurrence and a significantly lower recurrence rate compared with placebo. Trials registration (ClinicalTrials.gov) Identifier: NCT00105989.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Perahia 2009 reported a difference in the SF-36 mental component summary mean change score, favouring continuation of antidepressant: -5.74 (SE 1.2) in the discontinuation group (n = 142) and -1.11 (SE 1.11) in the continuation group (n = 146) (P = 0.002)”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Perahia 2009
In the citing paper
“and no difference in the SF-36 physical component summary score: 0.33 (SE 0.76) in the discontinuation group and -0.45 (SE 0.7) in the continuation group (P = 0.415).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Perahia 2009
In the citing paper
“Participants in the discontinuation group (n = 142) reported a higher score for Sheehan Disability Scale global functioning compared to those in the antidepressant group (n = 145) (mean change (SE) 2.06 (0.77) in the discontinuation group and -0.05 (0.71) in the antidepressant group; P = 0.029; increase in score signifies worsening).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Perahia 2009
In the citing paper
“Perahia 2009 (n = 288) reported no suicide attempts.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Perahia 2009
Citations
Cites
Still being checked.
Cited by
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136
Pergolizzi, J. V., Raffa, R. B., Taylor, R., Rodriguez, G., Nalamachu, S. R., & Langley, P. C. (2012) · Pain Practice · doi:10.1111/j.1533-2500.2012.00578.x · Cited by 118
Metadata
- Authors
- Perahia, D. G. S., Maina, G., Thase, M. E., Spann, M. E., Wang, F., Walker, D. J., & Detke, M. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-05-15
- Volume
- 70
- Issue
- 5
- Pages
- 706-716
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2119772787
- Semantic Scholar
- 548833f8bef5c57994e0e8f4f298d7cd024d5f36
- Cited by
- 47
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 4 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 3
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- duloxetine, major depressive disorder, depression recurrence, prevention, maintenance therapy, antidepressants, outpatients, time to recurrence, adverse events
- MeSH terms
- Duloxetine Hydrochloride, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Thiophenes, Prevalence, Selective Serotonin Reuptake Inhibitors, Sex Distribution, Diagnostic and Statistical Manual of Mental Disorders, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duloxetine in the Prevention of Depressive Recurrences: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.4088/jcp.08m04756
- The paper
- Perahia, D. G. S., Maina, G., Thase, M. E., Spann, M. E., Wang, F., Walker, D. J., & Detke, M. J. (2009). Duloxetine in the Prevention of Depressive Recurrences: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.08m04756
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.